Related Experiment Video
Updated: Apr 5, 2026
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.7K
Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes
Takehiro Hashikata1, Minako Yamaoka-Tojo2, Ryota Kakizaki3
1Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. t_hashikata@med.kitasato-u.ac.jp.
Heart and Vessels
|August 13, 2015
Summary
Teneligliptin, a DPP-4 inhibitor, improved heart function and endothelial function in type 2 diabetes patients. The drug also increased adiponectin levels, suggesting cardio-protective benefits.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Incretin hormones possess cytoprotective properties beyond glucose regulation.
- Type 2 diabetes mellitus (T2DM) is associated with cardiovascular complications.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors are used for T2DM management.
Purpose of the Study:
- To evaluate the effects of teneligliptin on left ventricular (LV) function in T2DM patients.
- To assess the impact of teneligliptin on endothelial function and adiponectin levels.
- To explore the potential cardio-protective effects of teneligliptin.
Main Methods:
- A 3-month study involving 29 T2DM patients not on incretin therapy.
- Administration of teneligliptin and assessment of LV function via echocardiography.
- Measurement of endothelial function using reactive hyperemia peripheral arterial tonometry (RH-PAT) and serum adiponectin levels.
Main Results:
- Teneligliptin significantly improved LV systolic and diastolic function (e.g., LV ejection fraction, E/e' ratio).
- Endothelial function, measured by RH-PAT index, showed significant improvement.
- Serum adiponectin levels increased significantly without changes in body weight or blood pressure.
Conclusions:
- Teneligliptin treatment positively impacts LV and endothelial function in T2DM patients.
- The observed improvements may be linked to increased adiponectin levels.
- Teneligliptin demonstrates potential cardio-protective effects in T2DM, warranting further investigation.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
962
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
962
01:06Oral Hypoglycemic Agents: Glinides
961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
564
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
564